IR&MEDIA

NEWS

Regenerative Medicine Company REV-MED Accelerates Expansion into the North and Central American Markets Through Participation in BIO USA 2025

관리자
9 Jun 2026
Views 205

31be7729c3304.png

REV-MED is expanding its global presence through participation in BIO International Convention (BIO USA 2025), the world’s largest biotechnology industry event, held in Boston, Massachusetts.

Through its participation in BIO USA 2025, the company aims to extend its reach beyond Latin America and Central America into the North American market, further strengthening its global influence.

As its initial target within the global autologous biologics sector, REV-MED has selected the biologics and regenerative medicine market, leveraging its proprietary autologous biologics extraction technologies to address the rapidly growing demand in orthopedic and regenerative medicine applications.

The company’s flagship platforms, including NovaStem BC and NovaStem BMAC, are recognized for their ability to precisely separate and concentrate biological components from blood and bone marrow, enabling use across a variety of clinical environments.

According to market forecasts cited by the company, the global biologics market is expected to grow from approximately USD 5.76 billion in 2025 to USD 8.28 billion by 2035, representing a compound annual growth rate (CAGR) of approximately 3.7%.

This growth is being driven by increasing demand associated with sports injuries, aging populations, and regenerative medicine applications. In particular, platelet-rich plasma (PRP) and bone marrow-derived treatment approaches continue to create new opportunities within the field.

North America remains the largest market segment, accounting for approximately 47.78% of the global biologics market. The region’s active adoption of advanced medical technologies and strong interest in regenerative medicine make it a strategically important market for REV-MED.

The United States continues to lead the sector through major healthcare institutions and research centers that actively conduct clinical research and product development.

Having already secured regulatory approvals and established credibility in key international markets including Japan, China, and Europe, REV-MED plans to use BIO USA 2025 as an opportunity to expand collaboration with healthcare professionals, researchers, and business partners throughout North America.

A company representative stated, “Based on our proprietary technologies and competitive strengths, we will continue strengthening our leadership position within the global regenerative medicine market.”

Source: Daily Medi

0 0